



Uni-Bio Science Appoints General Manager of Uni-Bio Science Healthcare and Senior Vice President of the Group

* * * *

Strengthens Sales Force and Boosts Sales Growth

(Hong Kong, 8 May 2017) – **Uni-Bio Science Group Limited** (“Uni-Bio Science” or the “Group;” HKEx code: 690) has today announced that Mr. Xue Wei has been appointed as General Manager of Uni-Bio Science Healthcare Limited and Senior Vice President of the Group, effective 8 May 2017. Uni-Bio Science Healthcare is the Group’s subsidiary specializing in Marketing and Sales and Distribution.

Mr. Xue has more than 20 years’ experience in executive positions in both MNCs and Domestic Pharmaceutical companies, including heading marketing, sales divisions and business units at Bayer and Fresenius Kabi. During his tenure, he was responsible for the successful launch of several key products and generated billions of revenues in Hong Kong dollars annually, creating one of the best performing business units in the whole industry. The Group strongly believes Mr. Xue, bringing with him his wealth of experience, will enable it to create business units in endocrinology to best support the Group’s latest launched Bokangtai (Mitiglinide tablet) and future blockbuster products, such as Uni-E4 and Uni-PTH. Prior to joining Uni-Bio Science, Mr. Xue was Vice President of the Health Insurance Sector of Fosun International Limited and the General Manager of Fosun’s wholly-owned subsidiary, StarE Health. His experience in the commercial insurance sector will provide unique insights that the Group needs to grow its commercial platform and align it with the “Healthy China 2020” 5-year healthcare reform roadmap, an effort of the regulators to promote a more comprehensive healthcare insurance system that can give the Chinese people greater protection.

Mr. Xue has graduated from Peking University majoring in Pharmacy and holds an MBA from Tsinghua University. He has served as a practicing hospital pharmacist before entering the commercial sector. With his extensive experience and rich industry knowledge, he is well-suited to lead Uni-Bio’s ongoing sales force expansion while enhancing the training of the sales force, ensuring sustained sales growth of our EGF products and chemical drugs, managing the future product launches and steering Uni-Bio’s sales and marketing plans through its partnerships with China Resources Zizhu Pharmaceutical and LUQA Pharmaceuticals.

Mr. Kingsley LEUNG, Chairman and Executive Director of Uni-Bio Science, said, *“I am delighted to announce the appointment of Mr. Xue as the General Manager of Uni-Bio Science Healthcare and Senior Vice President of the Group . His proven experience and industry expertise strengthens the Group’s sales force, enabling the team to achieve outstanding sales growth and accelerate business expansion in China. With Mr. Xue on board, we look forward to achieving promising outcomes for our partnerships with China Resources Zizhu Pharmaceutical and LUQA Pharmaceuticals and preparing for the future launch of our proprietary products in an ideal professional manner.”*

About Uni-Bio Science Group Limited (SEHK: 0690)

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center located in Dongguan, PRC is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments addressing the therapeutic areas of diabetes, ophthalmology and dermatology.

Media Enquiries:

Strategic Financial Relations Limited

Veron Ng Phone: +852 2864 4831
Angelus Lau Phone: +852 2864 4805
Elaine Wang Phone: +852 2864 4862
 Fax: +852 2527 1196

Email: veron.ng@sprg.com.hk
Email: angelus.lau@sprg.com.hk
Email: elaine.wang@sprg.com.hk

WeChat ID: Unibio-IR

心 創 造 新 醫 藥
LEADING GENUINE INNOVATION

